Καραμπέτσου Μαρία MD, PhD

Ακαδημαϊκές δημοσιεύσεις

• SLAMF1 engagement inhibits T cell-B cell interaction and diminishes IL-6 production and plasmablast differentiation in systemic lupus erythematosus, Beth Israel Deaconess Medical Center, Harvard Medical School (2019)
• Expression patterns of signaling lymphocytic activation molecule family members in peripheral blood mononuclear cell subsets in patients with systemic lupus erythematosus, Beth Israel Deaconess Medical Center, Harvard Medical School (2017)
• SLAMF7-engagement restores defective effector CD8+ T cells activity in response to foreign antigens in systemic lupus erythematosus. Arthritis and Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School (2017)
• CD4+ T cells from patients with SLE respond poorly to exogenous IL-2. , Beth Israel Deaconess Medical Center, Harvard Medical School (2017)
• ICER is requisite for Th17 differentiation., Beth Israel Deaconess Medical Center, Harvard Medical School (2016)
• Engagement of SLAMF3 enhances CD4+ T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus, Beth Israel Deaconess Medical Center, Harvard Medical School (2016)
• Decreased SAP Expression in T Cells from Patients with Systemic Lupus Erythematosus Contributes to Early Signaling Abnormalities and Reduced IL-2 Production, Beth Israel Deaconess Medical Center, Harvard Medical School (2015)
• Selective Loss of Signaling Lymphocytic Activation Molecule Family Member 4-Positive CD8+ T Cells Contributes to the Decreased Cytotoxic Cell Activity in Systemic Lupus Erythematosus, Beth Israel Deaconess Medical Center, Harvard Medical School (2016)
• Treatment with TNFα blockers induces phenotypical and functional aberrations in peripheral B cells, Department of Internal Medicine, Division of Rheumatology, Patras University Hospital, University of Patras (2011)
• Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis, Department of Internal Medicine, Division of Rheumatology, Patras University Hospital, University of Patras (2010)
• Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study, Department of Internal Medicine, Division of Rheumatology, Patras University Hospital, University of Patras (2009)